Shares of Healthcare Triangle (HCTI) slid 11% to $0.43 on Monday as investors braced for the growing possibility that the company may lose its Nasdaq listing entirely — a blow that would push the stock into the thinly traded over-the-counter market and likely trigger forced selling by institutional funds. Healthcare Triangle Stares Down Nasdaq Eviction — But Does a Company With Growing Revenue Deserve a Second Chance?

Shares plunged 11% to $0.43 as Healthcare Triangle's Nasdaq listing teetered on the edge. The exchange issued a formal delisting determination on October 1 for violating the $1.00 minimum bid-price rule, and the company's silence about whether it actually filed its appeal by the October 8 deadline left investors guessing whether Monday's session could be the stock's last on a major exchange.

  • A History of Reverse Splits Has Run Out of Road. Nasdaq issued the determination after notifying HCTI on October 1 that it was ineligible for a normal cure period because its cumulative reverse splits totaled 1-for-14,940. That staggering figure reflects three separate reverse splits — 1-for-10 in May 2023 , 1-for-249 in August 2025 , and 1-for-60 in February 2026 — each one meant to temporarily boost the share price above $1.00. Every time, the stock slid back. Nasdaq's rules bar companies from getting more time to comply if they've relied too heavily on share consolidation, and HCTI has exhausted that goodwill.

  • The Appeal Clock Has Likely Ticked, but Nobody Confirmed It. Without an appeal by October 8, trading would be suspended at the open on October 12, followed by a formal removal filing. HCTI said it intended to request a hearing, but no SEC filing or press release has confirmed submission. If the appeal was filed, it would freeze the suspension while a hearings panel decides. If it wasn't, the stock faces immediate exile to the over-the-counter market — where trading is thinner, institutional investors often cannot hold shares, and prices tend to fall further.

  • Revenue Is Growing, but the Balance Sheet Tells a Harsher Story. Q2 2026 revenue reached $9.19 million, up 158% year over year, with gross margin improving to 22.5%. Yet the company carries negative revenue growth historically, persistent losses, and negative equity.

EBITDA was -$4.07 million in a recent twelve-month period, and HCTI closed a $4.235 million convertible-note deal in June 2026 that converts at an 85% discount to market price — a structure that virtually guarantees further dilution.

  • What Delisting Actually Costs Shareholders. Moving to the OTC market shrinks the pool of eligible buyers, widens the gap between buy and sell prices, and often triggers automatic selling by index funds and compliance-bound institutions. For a company whose market cap was recently just $10.86 million , even modest forced selling could be devastating. The stock has already fallen 30% in a week, from $0.61 to $0.43, pricing in significant — but not total — listing risk.